Antiverse receive investment from IIC and Development Bank of Wales
Lucy Batizovsky | March 9, 2026 | News story | Research and Development | Antiverse, Wales, funding
As part of its $9.3m Series A funding round, Antiverse has received a joint equity investment by Innovation Investment Capital (IIC), the Cardiff Capital Region (CCR) backed fund and the Development Bank of Wales, alongside other investors.
Cardiff-based Antiverse applies advanced generative AI and machine learning to predict, design and optimise antibody-based drugs, reducing the time and cost of traditional discovery methods. The company’s platform supports programmes across oncology, immunology and infectious disease.
Murat Tunaboylu, Antiverse’s Co-Founder and CEO, said: “This investment not only enables us to scale our platform, grow our team and deepen partnerships with pharma and biotech leaders worldwide, but also positions Antiverse strongly for our next phase of growth.
“By strengthening our foundations at Series A, we are laying the groundwork for a successful Series B and the opportunity to bring our technology to an even broader global market.”
This recent investment by the Development Bank came from the £20m Wales Technology Seed Fund II. The Welsh Government financed fund offers equity investments between £100,000 and £350,000 for Welsh tech businesses and those relocating to Wales at proof-of-concept stage. The Development Bank has invested in Antiverse twice before, including providing early-stage seed capital in 2020.
IIC launched in November 2022, receiving an initial £50m from UK government funds and CCR. It aims to provide long-term capital for innovative and sustainable growth opportunities across CCR’s ten unitary authorities.
Kellie Beirne, CCR’s Chief Executive said: “Antiverse is a great example of the kind of cutting-edge innovation we want to see growing in our region. By combining AI with life sciences, the team is tackling some of the most important challenges in healthcare today.
“CCR is committed to investing in medical tech innovators and we are proud to support a business like Antiverse that is creating global impact from Cardiff.”
Related Content
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its …
Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform
UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance …
Academy of Medical Sciences invests record £7.6m into early-career biomedical researchers
The Academy of Medical Sciences has awarded £7.6m to support 62 early-career biomedical researchers across …
